Thermo Fisher Scientific (TMO) Current Deferred Revenue (2009 - 2026)

Thermo Fisher Scientific has disclosed Current Deferred Revenue across 18 years of filings, most recently posting $2.9 billion for Q1 2026.

• Quarterly Current Deferred Revenue rose 2.16% year-over-year to $2.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 billion (up 2.16% YoY) and the FY2025 annual result came in at $2.7 billion, down 4.98% from the prior year.
• Current Deferred Revenue advanced to $2.9 billion in Q1 2026, from $2.7 billion in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $2.9 billion in Q1 2026 and troughed at $2.5 billion in Q3 2023.
• A 5-year average of $2.7 billion and a median of $2.7 billion in 2023 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue soared 105.66% — and 2023, when it slipped 7.28%.
• Tracing TMO's Current Deferred Revenue over 5 years: stood at $2.6 billion in 2022, then rose by 3.38% to $2.7 billion in 2023, then climbed by 6.06% to $2.9 billion in 2024, then retreated by 4.98% to $2.7 billion in 2025, then climbed by 8.04% to $2.9 billion in 2026.
• Business Quant data shows TMO's Current Deferred Revenue at $2.9 billion in Q1 2026, $2.7 billion in Q4 2025, and $2.9 billion in Q3 2025.